Vaxart, Inc. (VXRT) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Vaxart, Inc. (VXRT) Bundle
Discover the true value of Vaxart, Inc. (VXRT) with our advanced DCF Calculator! Adjust key assumptions, explore various scenarios, and evaluate how different factors affect Vaxart, Inc. (VXRT) valuation – all within a single Excel template.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 9.9 | 4.0 | .9 | .1 | 7.4 | 5.1 | 3.5 | 2.4 | 1.7 | 1.1 |
Revenue Growth, % | 0 | -58.97 | -77.95 | -88 | 6796.26 | -31.23 | -31.23 | -31.23 | -31.23 | -31.23 |
EBITDA | -12.2 | -28.3 | -66.5 | -103.1 | -74.7 | -5.1 | -3.5 | -2.4 | -1.7 | -1.1 |
EBITDA, % | -123.41 | -698.52 | -7449.66 | -96372.9 | -1012.64 | -100 | -100 | -100 | -100 | -100 |
Depreciation | 3.6 | 1.8 | 2.4 | 3.3 | 8.6 | 3.9 | 2.7 | 1.8 | 1.3 | .9 |
Depreciation, % | 36.46 | 45.63 | 272.65 | 3053.27 | 116.87 | 76.42 | 76.42 | 76.42 | 76.42 | 76.42 |
EBIT | -15.8 | -30.1 | -68.9 | -106.4 | -83.3 | -5.1 | -3.5 | -2.4 | -1.7 | -1.1 |
EBIT, % | -159.88 | -744.14 | -7722.31 | -99426.17 | -1129.52 | -100 | -100 | -100 | -100 | -100 |
Total Cash | 13.5 | 126.9 | 166.5 | 93.7 | 39.7 | 5.1 | 3.5 | 2.4 | 1.7 | 1.1 |
Total Cash, percent | .0 | .0 | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 3.6 | .3 | .1 | .0 | 3.0 | 1.1 | .8 | .5 | .4 | .3 |
Account Receivables, % | 36.7 | 8.26 | 7.96 | 18.69 | 40.76 | 22.47 | 22.47 | 22.47 | 22.47 | 22.47 |
Inventories | .0 | .0 | .0 | 2.0 | .0 | 1.0 | .7 | .5 | .3 | .2 |
Inventories, % | 0.000010139931 | 0 | 0.000112107623 | 1869.16 | 0 | 20 | 20 | 20 | 20 | 20 |
Accounts Payable | .9 | 2.1 | 3.9 | 5.5 | 1.6 | 2.9 | 2.0 | 1.4 | .9 | .6 |
Accounts Payable, % | 8.64 | 52.72 | 434.08 | 5153.27 | 21.47 | 56.56 | 56.56 | 56.56 | 56.56 | 56.56 |
Capital Expenditure | -.9 | -1.2 | -5.2 | -9.6 | -1.9 | -2.7 | -1.8 | -1.3 | -.9 | -.6 |
Capital Expenditure, % | -8.62 | -30.23 | -578.14 | -8972.9 | -25.36 | -52.84 | -52.84 | -52.84 | -52.84 | -52.84 |
Tax Rate, % | -0.3175 | -0.3175 | -0.3175 | -0.3175 | -0.3175 | -0.3175 | -0.3175 | -0.3175 | -0.3175 | -0.3175 |
EBITAT | -16.2 | -30.3 | -69.0 | -106.5 | -83.6 | -5.1 | -3.5 | -2.4 | -1.7 | -1.1 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -16.2 | -25.1 | -69.7 | -113.1 | -81.8 | -1.7 | -2.9 | -2.0 | -1.4 | -.9 |
WACC, % | 7.31 | 7.31 | 7.31 | 7.31 | 7.31 | 7.31 | 7.31 | 7.31 | 7.31 | 7.31 |
PV UFCF | ||||||||||
SUM PV UFCF | -7.4 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | -1 | |||||||||
Terminal Value | -18 | |||||||||
Present Terminal Value | -13 | |||||||||
Enterprise Value | -20 | |||||||||
Net Debt | -8 | |||||||||
Equity Value | -12 | |||||||||
Diluted Shares Outstanding, MM | 145 | |||||||||
Equity Value Per Share | -0.08 |
What You Will Get
- Real VXRT Financial Data: Pre-filled with Vaxart, Inc.’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Vaxart, Inc.’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Data: Vaxart, Inc.'s historical financial reports and pre-filled projections.
- Customizable Parameters: Adjust inputs like WACC, tax rates, revenue growth, and EBITDA margins.
- Real-Time Calculations: View Vaxart, Inc.'s intrinsic value update instantly.
- Intuitive Visualizations: Dashboard graphs present valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file for Vaxart, Inc. (VXRT).
- Step 2: Review Vaxart’s pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model refresh in real-time as you modify assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose Vaxart, Inc. (VXRT) Calculator?
- Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses tailored for Vaxart, Inc. (VXRT).
- Customizable Inputs: Modify the highlighted cells to explore different financial scenarios.
- Detailed Insights: Automatically computes Vaxart's intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points for analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focusing on Vaxart, Inc. (VXRT).
Who Should Use This Product?
- Investors: Evaluate Vaxart, Inc. (VXRT) for informed buying or selling decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess future projections for Vaxart.
- Startup Founders: Understand the valuation strategies of biotech companies like Vaxart, Inc. (VXRT).
- Consultants: Create detailed valuation reports for clients focusing on Vaxart, Inc. (VXRT).
- Students and Educators: Utilize real-time data from Vaxart, Inc. (VXRT) to teach and practice valuation skills.
What the Vaxart Template Contains
- Preloaded VXRT Data: Historical and projected financial data, including revenue, net income, and research and development expenses.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.